Major Research Projects
home search

 

Abstract for the RCE

Bacillus anthracis Host Interactions

Discovery of Subunit Vaccine Candidates                             against Glanders

Alphavirus Vaccines for Biodefense

Novel Genetic Tools for Viral Biodefense

Development and Evaluation of Human
                     Brucellosis Vaccines

Rapid Diagnostic Tools for Q Fever

New Diagnostic Methods for Accute Rickettsial
                      Infections

Risks and Interventions for Pandemic Influenza

Development of Novel Pseudoinfectious Flavivirus                             Vaccines

Development of Diagnostic Reagents for the detection
                            of Francisella and
                             Francisella Infection

Toward Control of Rift Valley Fever Virus
                             Replication

Novel Vaccine Technology for Biodefense

Nucleocapsid-specific Small Molecule Inhibitors
                             of the Bunyaviridae

New Technologies for Creating Affinity Reagents

New Opportunities Projects

Identification and Characterization of Novel
                             Flavivirus Antivirals

Biosafety Containment Training Program

Passive Immunotherapeutics for
                             Select Agents

Preclinical Testing of YF17D/LAS, a Bivalent
                              Vaccine for Lassa and
                             Yellow Fever

 

Nucleocapsid-specific Small Molecule Inhibitors of the Bunyaviridae

 

Collaborating Institution: Univeristy of New Mexico, Albuquerque, NM

 

Principal Investigator: Antonito Panganiban, PhD

 

Co-Investigators: M. Ayoub Mir, PhD - University of New Mexico, Albuquerque, NM

 

Expected Product: Identify compounds to be developed into new antiviral agents for bunyaviruses.

 

Description: The Bunyaviridae family of viruses includes a set of Category A and C virus species. For the Bunyaviridae these include the members of the Hantavirus genus, as well as Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus. Current therapies against most of these viruses either do not exist or are only marginally efficient. Thus, it would be highly beneficial to identify and develop additional drugs directed at specific viral targets required for replication. The goal of this revised proposal is to refine and use an assay system for the identification of molecules that disrupt the function of the principle nucleocapsid protein of these viruses, and to carry out screening for such candidate drugs. The nucleocapsid protein (N) functions both in the process of RNA encapsidation during virus assembly and during genome replication in conjunction with the viral polymerase. Since these are essential steps in virus replication, disruption of one or both processes would effectively block virus propagation. Our basic work indicates that for the Bunyaviridae, the principle in vitro RNA substrate for N is the RNA panhandle formed by the hydrogen bonding of the genome termini. In vivo discrimination and encapsidation of minus strand viral RNAs likely requires high affinity interaction of N with the panhandle. Our approach will be to use this specific interaction as the basis of a rapid and convenient assay to identify molecules that block N function. This is likely to lead to the identification of a constellation of novel candidate molecules that interfere with the correct interaction of N with vRNA. Candidate molecules will be examined for their effect on cell viability and virus replication.